GB9700933D0 - Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis - Google Patents

Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis

Info

Publication number
GB9700933D0
GB9700933D0 GBGB9700933.6A GB9700933A GB9700933D0 GB 9700933 D0 GB9700933 D0 GB 9700933D0 GB 9700933 A GB9700933 A GB 9700933A GB 9700933 D0 GB9700933 D0 GB 9700933D0
Authority
GB
United Kingdom
Prior art keywords
osteoporosis
cancer
developing
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9700933.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to GBGB9700933.6A priority Critical patent/GB9700933D0/en
Publication of GB9700933D0 publication Critical patent/GB9700933D0/en
Priority to EP98900887A priority patent/EP0968432A1/en
Priority to JP53391398A priority patent/JP2001511783A/en
Priority to PCT/GB1998/000033 priority patent/WO1998032022A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9700933.6A 1997-01-17 1997-01-17 Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis Pending GB9700933D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB9700933.6A GB9700933D0 (en) 1997-01-17 1997-01-17 Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis
EP98900887A EP0968432A1 (en) 1997-01-17 1998-01-15 Growth factor-dependent diseases
JP53391398A JP2001511783A (en) 1997-01-17 1998-01-15 Growth factor dependent disease
PCT/GB1998/000033 WO1998032022A1 (en) 1997-01-17 1998-01-15 Growth factor-dependent diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9700933.6A GB9700933D0 (en) 1997-01-17 1997-01-17 Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis

Publications (1)

Publication Number Publication Date
GB9700933D0 true GB9700933D0 (en) 1997-03-05

Family

ID=10806150

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9700933.6A Pending GB9700933D0 (en) 1997-01-17 1997-01-17 Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis

Country Status (4)

Country Link
EP (1) EP0968432A1 (en)
JP (1) JP2001511783A (en)
GB (1) GB9700933D0 (en)
WO (1) WO1998032022A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213045A1 (en) * 2002-02-13 2003-09-04 The Trustees Of Columbia University In The City Of New York Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth
GB0206091D0 (en) * 2002-03-15 2002-04-24 Astrazeneca Ab New medical use
EP1560933A4 (en) * 2002-11-14 2007-11-21 Wyeth Corp Methods and compositions for treating neurological disorders

Also Published As

Publication number Publication date
EP0968432A1 (en) 2000-01-05
JP2001511783A (en) 2001-08-14
WO1998032022A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
GB9407135D0 (en) Treatment of osteoporosis
ZA957483B (en) Compounds and methods for the treatment of cancer
GR3036315T3 (en) Indolinone compounds for the treatment of disease
IL112455A0 (en) Combination treatment for osteoporosis
IL136515A0 (en) Combination effective for the treatment of impotence
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
HK1015357A1 (en) Process for the preparation of halogenated hydroxy diphenyl compounds
EP0828503A4 (en) Treatment for inhibiting the progression of autoimmune disease
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0101947A3 (en) Combination for the treatment of tumors
IL136953A0 (en) Apparatus for therapeutic electromagnetic treatment
GB9700933D0 (en) Process for developing or identifying drugs for the treatment or prevention of cancer or osteoporosis
HU9402578D0 (en) Medicament for treating or preventing cerebrovascular diseases
EP0981545A4 (en) Treatment of osteoporosis
ZA964465B (en) Use of alendronate for the prevention of osteoporosis
HUP0100365A3 (en) Combination therapy for the treatment of aids
GB2332849B (en) Apparatus for the treatment of soil
GB9819999D0 (en) Treatment of cancer
ZA964387B (en) Agent for the treatment of radiation injuries
IL120955A0 (en) Treatment of osteoporosis
IL136210A0 (en) Reagent for tumor therapy and/or imaging
EP1135141A4 (en) Phospholipase inhibitors for the treatment of cancer
GB2312375B (en) Agents for treatment of cancer
EP0976400A4 (en) Preventive or remedy for kidney diseases
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia